Key result
Ranolazine reduces infarct size and cardiac biomarkers via nitric oxide and adenosine-dependent pathways.
Why the study?
Does ranolazine induce cardioprotective effects similar to ischemic preconditioning in an isolated heart model of myocardial infarction?
Does ranolazine induce cardioprotective effects similar to ischemic preconditioning in an isolated heart model of myocardial infarction?
Answers are grounded in this paper and cite their sources.
Ranolazine provides cardioprotection against ischemia-reperfusion injury in an isolated heart model via pathways involving nitric oxide, adenosine, bradykinin, and ATP-dependent potassium channels, suggesting potential utility prior to interventional procedures.
PURPOSE: Hypothesis centered on the idea that ranolazine could induce responses similar to ischemic preconditioning, involving nitric oxide, adenosine, bradykinin, and adenosine triphosphate (ATP)-dependent potassium channels. METHODS: Ischemia-reperfusion injury was established using Langendroff technique. Thirty-minute ischemia and 120-minute reperfusion to coronary artery to isolated heart were model of myocardial infarction. There were studied the following groups: control (ischemia-reperfusion), ischemic preconditioning, ranolazine (10 µmol/L), ranolazine + L-NAME (30 µmol/L) and ranolazine + aminoguanidine (30 µmol/L), ranolazine + theophylline (50 µmol/L), ranolazine + aminophylline (50 µmol/L), ranolazine + icatibantl (100 µmol/L), ranolazine + bromelain (250 µmol/L), ranolazine + 5-hydroxydecanoate (30 µmol/L), and ranolazine + glimepiride (50 µmol/L) in perfusate. RESULTS: Ranolazine and ischemic preconditioning groups demonstrated cardioprotective effects by reducing infarct size, as well as levels of lactate dehydrogenase (LDH), creatine phosphokinase myoglobin (CK-MB), and troponin I and cardiac parameters like left ventricular developed pressure (LVDP) and left ventricular maximum rate of contraction (dP/dTmax). Maximum rate of relaxation (dP/dTmin) was improved. Conversely, treatments with L-NAME, aminoguanidine, theophylline, aminophylline, icatibant, bromelain, 5-hydroxydecanoate, and glimepiride increased infarct size, LDH, CK-MB, and troponin I levels, and cardiac parameters like LVDP, dP/dTmax, and dP/dTmin were depressed. This data provides evidence that ranolazine employs nitric oxide, adenosine, bradykinin, and ATP-dependent potassium channels as secondary messengers in cardioprotection. CONCLUSION: ranolazine can be a pharmacological alternative to surgical ischemic preconditioning utilized prior to interventional procedures like coronary artery bypass graft surgery and heart transplantation, offering improved patient compliance.
No takes yet. Share an insight, caveat, or question.
Tantray et al. (2026) studied Myocardial infarction (ischemia-reperfusion injury). Ranolazine vs. Control (ischemia-reperfusion) and ischemic preconditioning was evaluated on Infarct size, cardiac biomarkers (LDH, CK-MB, troponin I), and cardiac parameters (LVDP, dP/dTmax, dP/dTmin). Ranolazine demonstrated cardioprotective effects by reducing infarct size and cardiac biomarkers, mediated by nitric oxide, adenosine, bradykinin, and ATP-dependent potassium channels.
Synapse has enriched 10 related papers. Consider them for comparative context: